Skip to main content

CTOS 2024 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Hans Gelderblom, MD, PhD

Leiden University Medical Center, Netherlands

Poster(s):

(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)